NASDAQ:NKTX

Nkarta (NKTX) Stock Forecast, Price & News

$1.50

-0.19 (-11.24%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.48
▼
$1.64
50-Day Range: $1.59
▼
$2.29
52-Week Range: $1.48
▼
$14.57

Volume: 910,190 shs
Average Volume: 457,425 shs
Market Capitalization: $73.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Nkarta MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 1,144.4% Upside
$18.67 Price Target
Short Interest: Bearish
6.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$2,436 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.77) to ($2.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

461st out of 969 stocks

Pharmaceutical Preparations Industry

207th out of 455 stocks

3.4

Analyst's Opinion

Consensus Rating
Nkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Nkarta has a forecasted upside of 1,144.4% from its current price of $1.50.
Amount of Analyst Coverage
Nkarta has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.52% of the outstanding shares of Nkarta have been sold short.
Short Interest Ratio / Days to Cover
Nkarta has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Nkarta has recently increased by 4.58%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Nkarta does not currently pay a dividend.
Dividend Growth
Nkarta does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NKTX.

3.3

News and Social Media Coverage

News Sentiment
Nkarta has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Nkarta this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
7 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nkarta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,436.00 in company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Nkarta is held by insiders.
Percentage Held by Institutions
80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nkarta are expected to grow in the coming year, from ($2.77) to ($2.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nkarta is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nkarta is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nkarta has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nkarta (NASDAQ:NKTX) Stock

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Price History

30 days | 90 days | 365 days | Advanced Chart

NKTX Stock News Headlines

September 28, 2023 | markets.businessinsider.com

Promising Prospects for Ventyx Biosciences: A Comprehensive Analysis of VTX002’s Potential in Ulcerative Colitis Treatment

September 9, 2023 | benzinga.com

Nkarta Stock (NASDAQ:NKTX), Analyst Ratings, Price Targets, Predictions

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 14, 2023 | nasdaq.com

Mizuho Maintains Nkarta (NKTX) Buy Recommendation

August 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Ventyx Biosciences (VTYX)

August 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Nkarta (NKTX) Buy Recommendation

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Nkarta (NKTX)

August 11, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Nkarta

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 10, 2023 | finanznachrichten.de

Nkarta, Inc.: Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

August 10, 2023 | finance.yahoo.com

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

July 6, 2023 | msn.com

Nkarta (NKTX) Price Target Decreased by 25.24% to 20.02

July 5, 2023 | finance.yahoo.com

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

June 29, 2023 | msn.com

Raymond James Maintains Nkarta (NKTX) Outperform Recommendation

June 28, 2023 | finance.yahoo.com

Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks

June 28, 2023 | msn.com

HC Wainwright & Co. Maintains Nkarta (NKTX) Buy Recommendation

June 28, 2023 | msn.com

Needham Maintains Nkarta (NKTX) Buy Recommendation

June 27, 2023 | benzinga.com

Needham Maintains Buy on Nkarta, Lowers Price Target to $19

June 27, 2023 | bizjournals.com

Why Wall Street shaved a third of Peninsula cancer cell therapy company's value despite good news

June 27, 2023 | markets.businessinsider.com

NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline

June 27, 2023 | markets.businessinsider.com

Needham Keeps Their Buy Rating on Nkarta (NKTX)

June 27, 2023 | msn.com

Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors

June 27, 2023 | msn.com

Nkarta off 34% after updating early-stage data for leukemia therapy

June 27, 2023 | markets.businessinsider.com

Analyst Expectations for Nkarta's Future

June 27, 2023 | finance.yahoo.com

Why Shares of Nkarta Are Slumping Tuesday

June 27, 2023 | finance.yahoo.com

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

June 26, 2023 | finance.yahoo.com

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

See More Headlines

Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

NKTX Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NKTX
CUSIP: N/A
CIK: 1787400
Web: www.nkartatx.com
Phone: 925-407-1049
Fax: N/A
Employees: 169
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.67
High Stock Price Forecast: $26.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +1,144.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -34.83%
Return on Assets: -26.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.77
Quick Ratio: 10.77

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.63 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 49,060,000
Free Float: 46,311,000
Market Cap: $73.59 million
Optionable: Not Optionable
Beta: -0.06

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Paul J. Hastings (Age 63)
CEO, Pres & Director
Comp: $938.41k

Dr. Alicia J. Hager (Age 53)
Chief Legal Officer & Corp. Sec.
Comp: $590.94k

Ms. Alyssa Levin C.A. (Age 38)
CPA, Chief Financial & Bus. Officer and Principal Accounting Officer

Dr. Ralph Brandenberger Ph.D. (Age 54)
Chief Technical Officer

Dr. James Trager Ph.D. (Age 59)
Ph.D., Chief Scientific Officer

Ms. Yvonne Li M.B.A. (Age 63)
Chief Admin. Officer

Mr. Greg Mann
VP of Public Affairs and Investor Relations

Dr. David R. Shook M.D. (Age 45)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTX Stock - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NKTX shares.
View NKTX analyst ratings or view top-rated stocks.
What is Nkarta's stock price forecast for 2023?: 5 brokers have issued 1 year target prices for Nkarta's shares. Their NKTX share price forecasts range from $15.00 to $26.00. On average, they expect the company's share price to reach $18.67 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price.
View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts.
How have NKTX shares performed in 2023?: Nkarta's stock was trading at $5.99 at the beginning of the year. Since then, NKTX stock has decreased by 75.0% and is now trading at $1.50.
View the best growth stocks for 2023 here.
When is Nkarta's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NKTX earnings forecast.
How were Nkarta's earnings last quarter?: Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01.
What other stocks do shareholders of Nkarta own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?: (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.
What is Nkarta's stock symbol?: Nkarta trades on the NASDAQ under the ticker symbol "NKTX."
Who are Nkarta's major shareholders?: Nkarta's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (9.63%), BlackRock Inc. (6.20%), Geode Capital Management LLC (1.35%), State Street Corp (1.22%), JPMorgan Chase & Co. (0.78%) and Barclays PLC (0.77%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends.
How do I buy shares of Nkarta?: Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nkarta's stock price today?: One share of NKTX stock can currently be purchased for approximately $1.50.
How much money does Nkarta make?: Nkarta (NASDAQ:NKTX) has a market capitalization of $73.59 million. The company earns $-113,840,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.
How many employees does Nkarta have?: The company employs 169 workers across the globe.
How can I contact Nkarta?: Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.nkartatx.com. The company can be reached via phone at 925-407-1049 or via email at gmann@nkartatx.com.

This page (NASDAQ:NKTX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nkarta (NKTX) Stock Forecast, Price & News

Nkarta MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Nkarta (NASDAQ:NKTX) Stock

NKTX Price History

NKTX Stock News Headlines

NKTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NKTX Stock - Frequently Asked Questions

Overall MarketRank^™